No Data
No Data
Greenwich LifeSciences Raises $2.5M, Issues Shares to CEO
Express News | Greenwich Lifesciences Announces $2.5 Million Private Placement
H.C. Wainwright Maintains Greenwich LifeSciences(GLSI.US) With Buy Rating, Maintains Target Price $36
H.C. Wainwright analyst Yi Chen maintains $Greenwich LifeSciences(GLSI.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success rate of 27.0%
Greenwich LifeSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 173.14% HC Wainwright & Co. → $36 Reiterates Buy → Buy 02/28/2024 173.14% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
Greenwich LifeSciences | 10-Q: Quarterly report
No Data